A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer

(2019) Joyce F. Liu et al.   GYNECOLOGIC ONCOLOGY

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

(2019) Hyejin Choi et al.   Cell Reports

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition

(2019) Cretella et al.   Cancers

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

(2019) Shannon N. Westin et al.   GYNECOLOGIC ONCOLOGY

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

(2017) Alain P. Algazi et al.   Pigment Cell & Melanoma Research

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

(2016) D. P. Modest et al.   ANNALS OF ONCOLOGY

PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells

(2016) Natalia Alonso et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer

(2016) Bhuvaneswari Ramaswamy et al.   CANCER RESEARCH

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

(2016) Lee S. Rosen et al.   INVESTIGATIONAL NEW DRUGS

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer

(2016) J.-Y. Kim et al.   MOLECULAR CANCER RESEARCH

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

(2016) Cristina Saura et al.   Cancer Discovery

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

(2015) Xiaolin Nan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crosstalk between ERK, AKT, and cell survival

(2014) Paul Dent   CANCER BIOLOGY & THERAPY

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

(2014) A. W. Tolcher et al.   CLINICAL CANCER RESEARCH

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

(2012) Edna F. Choo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract 873: Combined targeting of Akt and MEK with the Akt inhibitor GDC-0068 and MEK inhibitor GDC-0973 demonstrates synergistic anti-tumor effects

(2012) Michelle A. Nannini et al.   CANCER RESEARCH

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

(2010) C. G. Fedele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deregulation of the Akt Pathway in Human Cancer

(2008) Eriko Tokunaga et al.   CURRENT CANCER DRUG TARGETS

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA